Follow-up includes clinical assessment, serum carcinoembryonic antigen (CEA) monitoring, and interval imaging (CT chest/abdomen/pelvis) as per colorectal cancer surveillance guidelines. The gene discussed is CEACAM5; the disease is colorectal cancer.